Teva Pharmaceutical Industries (NYSE: TEVA) has recently received a number of price target changes and ratings updates:

  • 12/5/2017 – Teva Pharmaceutical Industries was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/29/2017 – Teva Pharmaceutical Industries was given a new $11.00 price target on by analysts at Royal Bank Of Canada. They now have a “sell” rating on the stock.
  • 11/29/2017 – Teva Pharmaceutical Industries had its price target raised by analysts at Mizuho from $12.00 to $16.00. They now have a “neutral” rating on the stock.
  • 11/28/2017 – Teva Pharmaceutical Industries was given a new $16.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
  • 11/27/2017 – Teva Pharmaceutical Industries was given a new $10.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 11/25/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Wells Fargo & Company.
  • 11/17/2017 – Teva Pharmaceutical Industries had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $12.00 price target on the stock, down previously from $15.00.
  • 11/14/2017 – Teva Pharmaceutical Industries was given a new $10.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 11/13/2017 – Teva Pharmaceutical Industries was downgraded by analysts at J P Morgan Chase & Co from a “neutral” rating to an “underweight” rating. They now have a $11.00 price target on the stock, down previously from $11.48.
  • 11/12/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 11/7/2017 – Teva Pharmaceutical Industries was downgraded by analysts at from a “hold” rating to a “reduce” rating.
  • 11/6/2017 – Teva Pharmaceutical Industries had its price target lowered by analysts at Susquehanna Bancshares Inc from $20.00 to $14.00. They now have a “positive” rating on the stock.
  • 11/6/2017 – Teva Pharmaceutical Industries had its “underperform” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $8.00 price target on the stock, down previously from $14.00.
  • 11/5/2017 – Teva Pharmaceutical Industries had its price target raised by analysts at Royal Bank Of Canada from $8.00 to $13.00. They now have an “underperform” rating on the stock.
  • 11/3/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $12.00 price target on the stock.
  • 11/3/2017 – Teva Pharmaceutical Industries had its price target lowered by analysts at Morgan Stanley from $14.00 to $7.00. They now have an “underweight” rating on the stock.
  • 11/3/2017 – Teva Pharmaceutical Industries was downgraded by analysts at Deutsche Bank AG from a “buy” rating to a “hold” rating. They now have a $14.00 price target on the stock.
  • 11/2/2017 – Teva Pharmaceutical Industries was downgraded by analysts at Wells Fargo & Company to a “market perform” rating. They now have a $11.36 price target on the stock, down previously from $17.00.
  • 10/30/2017 – Teva Pharmaceutical Industries had its “hold” rating reaffirmed by analysts at Mizuho. They now have a $15.00 price target on the stock.
  • 10/30/2017 – Teva Pharmaceutical Industries had its “underperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $13.00 price target on the stock, down previously from $15.00.
  • 10/26/2017 – Teva Pharmaceutical Industries was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock. They wrote, “Today Mylan (MYL; Neutral) announced the UK High Court of Justice found all claims of Teva’s patent EP ‘355 relating to Copaxone 40mg/mL invalid based on obviousness.””
  • 10/25/2017 – Teva Pharmaceutical Industries was given a new $38.00 price target on by analysts at Evercore ISI. They now have a “buy” rating on the stock.
  • 10/20/2017 – Teva Pharmaceutical Industries was given a new $15.00 price target on by analysts at Royal Bank Of Canada. They now have a “sell” rating on the stock.
  • 10/20/2017 – Teva Pharmaceutical Industries was given a new $19.00 price target on by analysts at Barclays PLC. They now have a “hold” rating on the stock.
  • 10/19/2017 – Teva Pharmaceutical Industries was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 10/13/2017 – Teva Pharmaceutical Industries was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down $0.74 during trading hours on Thursday, hitting $14.32. The stock had a trading volume of 22,053,602 shares, compared to its average volume of 15,674,351. Teva Pharmaceutical Industries Limited has a 52-week low of $10.85 and a 52-week high of $38.31. The stock has a market cap of $15,300.96, a price-to-earnings ratio of 3.48 and a beta of 0.55. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.085 dividend. The ex-dividend date is Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a yield of 2.37%. Teva Pharmaceutical Industries’s payout ratio is currently -12.10%.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.